(Q31976692)

5 July 2017

1 reference

title

Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression (English)

1 reference

5 July 2017

0 references

1 reference

Fleishaker JC

1

1 reference

5 July 2017

publication date

1 December 2000

1 reference

Clinical Pharmacokinetics

5 July 2017

published in

1 reference

5 July 2017

volume

39

1 reference

5 July 2017

issue

6

1 reference

5 July 2017

page(s)

413-427

1 reference

The role of norepinephrine in the treatment of depression

5 July 2017

cites work

1 reference

12 December 2020

Dose proportionality of reboxetine enantiomers in healthy male volunteers

1 reference

12 December 2020

Pharmacokinetics of reboxetine in elderly patients with depressive disorders

1 reference

12 December 2020

Hemodynamic effects of reboxetine in healthy male volunteers

1 reference

12 December 2020

Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications

1 reference

12 December 2020

Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding

1 reference

12 December 2020

Differential pharmacology of newer antidepressants.

1 reference

12 December 2020

Disseminated intravascular coagulation and acute myoglobinuric renal failure: a consequence of the serotonergic syndrome

1 reference

12 December 2020

Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations

1 reference

12 December 2020

Combined MAOI-tricyclic antidepressant treatment: a reevaluation.

1 reference

12 December 2020

Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics

1 reference

12 December 2020

Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes

1 reference

12 December 2020

Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency

1 reference

12 December 2020

Stereoselective and species‐dependent kinetics of reboxetine in mouse and rat

1 reference

12 December 2020

Alprazolam in end-stage renal disease: I. Pharmacokinetics

1 reference

12 December 2020

Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man.

1 reference

12 December 2020

Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies

1 reference

12 December 2020

No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers

1 reference

12 December 2020

Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor

1 reference

12 December 2020

Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder

1 reference

12 December 2020

Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans

1 reference

12 December 2020

Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

1 reference

12 December 2020

Adverse consequences of fluoxetine-MAOI combination therapy

1 reference

12 December 2020

10.2165/00003088-200039060-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

5 July 2017

1012132477

0 references

1 reference